IRIS
SOTA, JURGEN
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.280
EU - Europa 5.429
AS - Asia 4.314
SA - Sud America 889
AF - Africa 270
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 1
Totale 17.200
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.161
RU - Federazione Russa 1.483
SG - Singapore 1.387
CN - Cina 1.187
GB - Regno Unito 1.129
IT - Italia 850
BR - Brasile 717
VN - Vietnam 567
IE - Irlanda 528
HK - Hong Kong 348
FR - Francia 293
SE - Svezia 270
KR - Corea 249
DE - Germania 242
FI - Finlandia 176
UA - Ucraina 175
IN - India 145
ZA - Sudafrica 131
TR - Turchia 83
AR - Argentina 57
CA - Canada 52
NL - Olanda 52
IQ - Iraq 51
BD - Bangladesh 50
MX - Messico 47
PL - Polonia 45
JP - Giappone 41
PK - Pakistan 39
ES - Italia 32
EC - Ecuador 29
AT - Austria 27
BE - Belgio 26
KE - Kenya 26
CI - Costa d'Avorio 24
CZ - Repubblica Ceca 22
ID - Indonesia 22
VE - Venezuela 22
MA - Marocco 21
AU - Australia 17
CO - Colombia 17
IR - Iran 16
EG - Egitto 15
SA - Arabia Saudita 15
UZ - Uzbekistan 15
DZ - Algeria 14
NG - Nigeria 14
CL - Cile 13
NP - Nepal 13
PE - Perù 13
AE - Emirati Arabi Uniti 11
JO - Giordania 11
PH - Filippine 10
TN - Tunisia 10
CH - Svizzera 8
LB - Libano 8
PY - Paraguay 8
LT - Lituania 7
AL - Albania 6
DK - Danimarca 6
JM - Giamaica 6
RO - Romania 6
UY - Uruguay 6
EE - Estonia 5
IL - Israele 5
MY - Malesia 5
RS - Serbia 5
AM - Armenia 4
AZ - Azerbaigian 4
BH - Bahrain 4
BO - Bolivia 4
BY - Bielorussia 4
ET - Etiopia 4
GR - Grecia 4
HU - Ungheria 4
LV - Lettonia 4
TH - Thailandia 4
CR - Costa Rica 3
GY - Guiana 3
NO - Norvegia 3
OM - Oman 3
PS - Palestinian Territory 3
PT - Portogallo 3
TT - Trinidad e Tobago 3
CG - Congo 2
CY - Cipro 2
KG - Kirghizistan 2
KW - Kuwait 2
KZ - Kazakistan 2
LU - Lussemburgo 2
MD - Moldavia 2
MK - Macedonia 2
NI - Nicaragua 2
PA - Panama 2
TG - Togo 2
TM - Turkmenistan 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BW - Botswana 1
CM - Camerun 1
Totale 17.181
Salva come PNG Salva come JPEG
Città #
Dallas 1.187
Southend 965
Singapore 823
Dublin 517
Santa Clara 439
Ashburn 426
Moscow 415
Fairfield 405
Hefei 380
Hong Kong 323
San Jose 298
Beijing 252
Seoul 249
Woodbridge 227
Siena 189
Chandler 178
Ho Chi Minh City 178
Menlo Park 176
Houston 174
Wilmington 153
New York 152
Ann Arbor 150
Seattle 142
Cambridge 138
Los Angeles 138
The Dalles 136
Hanoi 135
Jacksonville 135
Lauterbourg 127
Council Bluffs 123
Milan 119
Johannesburg 118
Helsinki 105
Princeton 85
Munich 83
São Paulo 66
Dearborn 60
Rome 60
Bengaluru 51
Dong Ket 49
Orem 48
Buffalo 47
Chicago 45
Redondo Beach 45
Lappeenranta 43
Nanjing 43
San Mateo 42
Warsaw 34
Da Nang 33
Florence 31
Nuremberg 31
Frankfurt am Main 30
London 30
Tokyo 30
Shanghai 29
San Diego 27
Boardman 26
Guangzhou 26
Abidjan 24
Brussels 24
Chennai 23
Izmir 23
Istanbul 22
Columbus 21
Montreal 20
Turku 20
Portsmouth 19
Rio de Janeiro 19
Düsseldorf 18
Amsterdam 17
Brooklyn 17
Denver 17
Mexico City 17
San Francisco 17
Nanchang 16
Campinas 15
Haiphong 15
Manchester 15
Stockholm 15
Atlanta 14
Baghdad 14
Tashkent 14
Abuja 13
Belo Horizonte 13
Boston 13
Jinan 13
Mumbai 13
Washington 13
Hebei 12
Phoenix 12
Shenyang 12
Amman 11
Ankara 11
Biên Hòa 11
Jiaxing 11
Nairobi 11
Sydney 11
Brasília 10
Curitiba 10
Hải Dương 10
Totale 11.412
Salva come PNG Salva come JPEG
Nome #
Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: A four-year follow-up study 342
Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis 329
Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients 326
Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis 312
Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review 311
Auditory involvement in Behcet’s disease: relationship with demographic, clinical, and therapeutic characteristics 308
Ten-Year Retention Rate of Infliximab in Patients with Behçet’s Disease-Related Uveitis 308
Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies 283
Quality of life impairment in Behçet’s disease and relationship with disease activity: a prospective study 270
The diagnostic evaluation of patients with a suspected hereditary periodic fever syndrome: experience from a referral center in Italy 262
Behçet’s syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics 262
Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet’s Disease 244
Correlation of Serum Amyloid-A Levels, Clinical Manifestations, Treatment, and Disease Activity in Patients with Behçet's Disease 238
The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease 237
Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study 236
Treatment options for periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome in children and adults: a narrative review 235
A novel grey scale and Power Doppler ultrasonographic score for idiopathic inflammatory myopathies: Siena Myositis Ultrasound Grading Scale 234
Predictors of sustained clinical response in patients with Behçet’s disease-related uveitis treated with infliximab and adalimumab 233
Impact of Uveitis on Quality of Life: A Prospective Study from a Tertiary Referral Rheumatology-Ophthalmology Collaborative Uveitis Center in Italy 230
The eye involvement in monogenic autoinflammatory diseases: Literature review and update 224
Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registry 220
A patient-driven registry on Behçet’s disease: the AIDA for patients pilot project 216
Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature 215
IL-6 blockade in the management of non-infectious uveitis 206
Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease 201
Development and implementation of the AIDA international registry for patients with Schnitzler's syndrome 199
Axial spondyloarthritis in patients with recurrent fever attacks: data from the AIDA network registry for undifferentiated autoInflammatory diseases (USAIDs) 195
Development and implementation of the AIDA international registry for patients with non-infectious uveitis 195
Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry 192
Long-Term Outcomes of Behçet's Syndrome-Related Uveitis: A Monocentric Italian Experience 192
Development and implementation of the AIDA International Registry for patients with Behçet's disease 190
The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases 189
Clinical profile and evolution of patients with juvenile-onset Behçet's syndrome over a 25-year period: insights from the AIDA network 183
Relapsing Polychondritis: an Update on Pathogenesis, Clinical Features, Diagnostic Tools, and Therapeutic Perspectives 180
Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes 171
Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers 169
Role of Colchicine Treatment in Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS): Real-Life Data from the AIDA Network 165
Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis 163
Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: real-life experience from the international AIDA registry 161
Dry eye disease and spondyloarthritis: expanding the spectrum of systemic inflammatory disorders associated with ocular surface disease. Data from the international AIDA Network Spondyloarthritis Registry 161
Anti-dense fine speckled 70 antibodies in primary Sjögren's syndrome 157
Impact of HLA-B51 on Uveitis and Retinal Vasculitis: Data from the AIDA International Network Registries on Ocular Inflammatory Disorders 152
Impact of HLA-B51 on uveitis and retinal vasculitis: data from the AIDA International Network Registries on ocular inflammatory disorders 152
Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network 151
Development and Implementation of the AIDA International Registry for Patients With Undifferentiated Systemic AutoInflammatory Diseases 148
Development and implementation of the AIDA international registry for patients with non-infectious scleritis 148
Comparing biologic options for the management of Behcet's disease-related uveitis 145
Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy 145
Adalimumab Monotherapy or Combination Therapy With Methotrexate in Paediatric Uveitis: Data From the AIDA Network Uveitis Registry 144
Serum immunoglobulin D levels in patients with Behçet's disease according to different clinical manifestations 144
Biologic drugs in the treatment of polyarteritis nodosa and deficit of adenosine deaminase 2: a narrative review 141
Accrual of organ damage in Behçet’s syndrome: trajectory, associated factors, and impact on patients’ quality of life over a 2-year prospective follow-up study 141
Development and implementation of the AIDA International Registry for patients with Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis syndrome 140
The role of biosimilars in uveitis: Long-term real-world outcomes of the switch from original to biosimilar TNF-alpha inhibitors 139
Development and Implementation of the AIDA International Registry for Patients With VEXAS Syndrome 138
Biotechnological agents for patients with tumor necrosis factor receptor associated periodic syndrome—therapeutic outcome and predictors of response: real-life data from the AIDA Network 135
Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF- α Receptor - Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network 134
Musculoskeletal manifestations in children with Behçet's syndrome: data from the AIDA Network Behçet's Syndrome Registry 132
Development and implementation of the AIDA international registry for patients with Still's disease 131
Efficacy and safety of abatacept in a patient with rheumatoid arthritis and concomitant Staphylococcus aureus osteomyelitis 131
Efficacy and safety of adalimumab in pediatric non-infectious non-anterior uveitis: real-life experience from the International AIDA Network Uveitis Registry 130
Unfolding dermatologic spectrum of Behçet’s disease in Italy: real-life data from the International AIDA Network Behçet’s disease Registry 130
Ocular Manifestations in Juvenile Behçet’s Disease: A Registry-Based Analysis from the AIDA Network 130
The diagnostic role of pathergy test in patients with Behçet’s disease from the Western Europe 129
Updated overview of molecular pathways involved in the most common monogenic autoinflammatory diseases 129
The Role of Multimodality Imaging in Monitoring Disease Activity and Therapeutic Response to Tocilizumab in Giant Cell Arteritis 129
Development and implementation of the international AIDA network spondylarthritis registry 128
Effectiveness and Safety of Biosimilars in Pediatric Non-infectious Uveitis: Real-Life Data from the International AIDA Network Uveitis Registry 128
Autoinflammatory diseases and the kidney 125
Influence of gender on Behçet's disease phenotype and irreversible organ damage: Data from the International AIDA Network Behçet's Disease Registry 124
Biologic therapies and small molecules for the management of non-infectious scleritis: a narrative review 123
Efficacy of monoclonal anti-tumour necrosis factor-α antibodies in uveitic macular oedema 121
The clinical assessment of lung involvement in patients with Still’s disease, results from the multicentre international AIDA Network Still's Disease Registry 120
Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network 120
The current status of biological treatment for uveitis 120
Power and spectral Doppler ultrasound in suspected active sacroiliitis: A comparison with magnetic resonance imaging as gold standard 119
Tocilizumab Vs Methotrexate in a Cohort of Patients Affected by Active GCA: A Comparative Clinical and Ultrasonographic Study 119
Efficacy of anti-tumour necrosis factor-α monoclonal antibodies in patients with non-infectious anterior uveitis 119
Musculoskeletal manifestations in hereditary periodic fever syndromes 118
Risk for cancer development in familial Mediterranean fever and associated predisposing factors: an ambidirectional cohort study from the international AIDA network registries 115
The role of biologic agents in the management of pediatric-onset noninfectious posterior scleritis 115
Polidistrectual videocapillaroscopic evaluation in a patient with prolidase deficiency 112
Efficacy and Safety of Upadacitinib in Rheumatoid Arthritis: Real-Life Experience from a Prospective Longitudinal Multicentric Study 111
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response 111
Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: a prospective cohort study from the international AIDA network registries 110
Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease 110
Efficacy of canakinumab in patients with Still’s disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still’s Disease 107
Efficacy and safety of tocilizumab in adult-onset Still's disease: real-life experience from the international AIDA registry 104
Serum Interleukin-36 α as a Candidate Biomarker to Distinguish Behçet’s Syndrome and Psoriatic Arthritis 102
Still’s disease continuum from childhood to elderly: data from the international AIDA Network Still’s disease registry 100
Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry 99
New potential weapons for refractory scleritis in the era of targeted therapy 99
Differential serum levels of interleukin-37 in patients with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) 98
Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis 97
Preliminary data revealing efficacy of Streptococcus salivarius K12 (SSK12) in Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome: a multicenter study from the AIDA Network PFAPA syndrome registry 96
Predictors of proteinuria, amyloidosis and kidney failure in familial Mediterranean fever: data from the International AIDA Network Registry 88
Empowering patients in the therapeutic decision-making process: a glance into Behçet's syndrome 87
The autoinflammatory diseases alliance registry of monogenic autoinflammatory diseases 87
Effectiveness of SB5, an adalimumab biosimilar, in patients with noninfectious uveitis: a real-life monocentric experience 86
Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission 84
Totale 16.514
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.880
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.880
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021278 0 0 0 0 0 0 0 0 0 116 43 119
2021/2022822 72 112 64 55 45 9 36 32 47 78 104 168
2022/2023804 57 71 132 94 57 153 28 63 72 12 37 28
2023/20241.062 39 24 91 56 32 298 302 55 12 18 48 87
2024/20253.577 289 145 354 151 406 209 164 200 272 183 318 886
2025/20267.974 645 1.233 1.057 1.111 1.439 305 1.077 303 330 474 0 0
Totale 17.628